High-intensity focused ultrasound shows efficacy as salvage therapy post-external beam radiation therapy

Salvage high-intensity focused ultrasound (HIFU) appears to be an effective treatment option for locally recurrent prostate cancer after primary external beam radiation therapy (EBRT), data from analyses of 6-year oncologic outcomes show.

Related Videos

Related Content

Advertisement

January 24th 2025

How to bill for placement of a peri-rectal spacer

Jonathan Rubenstein, MD Mark Painter

"Please note that although this starts out as a balloon rather than just the injection of a biodegradable product, this device is actually fully biodegradable and is absorbed within 6 months of insertion," write Jonathan Rubenstein, MD, and Mark Painter.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 24th 2025

Urogynecology for the Advanced Practice Provider

American Urogynecologic Society

Join AUGS in Nashville, TN, or virtually, April 24-26 for this annual course!

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 24th 2025

FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer

Hannah Clarke

64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.

January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.

Related Content

Advertisement

January 24th 2025

How to bill for placement of a peri-rectal spacer

Jonathan Rubenstein, MD Mark Painter

"Please note that although this starts out as a balloon rather than just the injection of a biodegradable product, this device is actually fully biodegradable and is absorbed within 6 months of insertion," write Jonathan Rubenstein, MD, and Mark Painter.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 24th 2025

Urogynecology for the Advanced Practice Provider

American Urogynecologic Society

Join AUGS in Nashville, TN, or virtually, April 24-26 for this annual course!

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 24th 2025

FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer

Hannah Clarke

64Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.

January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke

Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.